Jideytro (zidesamtinib)

Where it stands

According to the official records, the FDA approved Jideytro (zidesamtinib) in the US on 2026-07-22. The sponsor is Nuvalent. The FDA describes it as a new medicine, and the dosage form is a tablet.

The records give no therapeutic area and no indication. This analysis therefore cannot say which patients the product is approved to treat, at what dose, or under what conditions of use. The approved labeling would settle those points.

The records show no CHMP opinion date. They contain no EU milestones, so EU status cannot be assessed from this data.

Regulatory pathway and designations

The record lists one milestone, an FDA approval under NDA220185. The product carries the New molecular entity designation. In general, this means the active ingredient had not previously been approved by the FDA in any product. New molecular entities go through a full New Drug Application review.

The records do not say whether any expedited programs applied, such as priority review, breakthrough therapy, fast track or accelerated approval. They do not give the review timeline or the PDUFA goal date. They also do not say whether approval is full or conditional, or whether post-marketing requirements were imposed. None of these should be inferred.

Safety and pharmacovigilance

The records contain no information on safety, such as warnings, boxed warnings, risk management requirements or post-marketing commitments, so this section cannot be assessed from the data provided.

What to watch

The first priority is the full FDA-approved prescribing information and approval documents. They would confirm the indication, the dosing, the safety language and any post-marketing requirements, all of which are missing from the records.

Further points to check are Nuvalent's launch and market-access communications and any regulatory filings outside the US. The records show no EU or other ex-US activity, so any such progress would need to be confirmed from official sources as it occurs.